Votre navigateur ne supporte pas les CSS.
Si des images s'affichent ci-dessous, nous vous prions de ne pas en tenir compte.

Mot de passe:

Where is the Biotech industry going ?
Discussion around the Ernst & Young
Beyond Borders 2012 global biotech report
Tuesday June 26th - Corsier-sur-Vevey
Partager l'événement
In a global economy still affected by the ever renewed financial difficulties of the Euro zone, the biotech & pharma industry does not stand out as an exception. Public healthcare spendings are under pressure and as a consequence, so is the industry. Responding to growing medical needs while containing the costs is more than ever a challenging endeavour for our societies.

Today the biotech and pharmaceutical companies can leverage the extraordinary advances currently happening in the life sciences, and they clearly want to raise up to the challenge. Numerous efforts and creativity are being deployed throughout the industry to improve productivity, reduce costs and boost innovation. In this context, partnerships of different kinds are one of the promising approaches often taken to try to overcome the hurdles of the complex R&D process.

How can collaborations and partnerships reduce risk, broaden the knowledge base and improve the success rates of the drug discovery and development process? What is the way forward to deliver innovative treatments to patients?

This BioFirst, organized in collaboration with Merck Serono and Ernst & Young, will take the pulse of the industry and distinguished guests from the Swiss biotech community will provide insights into these questions.

   + free registration         please wait       - unregister me please     please wait      
Liste des participants
Vous devez être identifié en tant que membre Premium pour continuer
Je m'identifie
Liste des participants
Devenez membre Premium pour consulter la liste des participants
En savoir plus
Presentation of the Ernst & Young's 2012 Biotech Report

Jürg Zürcher
Biotech Industry Leader for EMEIA, Ernst & Young


Mark Hawkins
Partner Audit Services, Ernst & Young

Panel moderated by Mark Hawkins and Jürg Zürcher

Philippe Lopes-Fernandes
Vice-President Global Business Development, Merck Serono


David Deperthes
Business Development & Licensing Director, Debiopharm


Florian Wurm
Professor for Biotechnology, EPFL and Founder, CSO and interim CEO of ExcellGene

View Details
Hide details
And also :
  • Welcome adress by Tomas Roztocil, PhD Manager External Relations, Merck Serono
Tomas Roztocil
PhD Manager External Relations Merck Serono
Merck Serono
Merck Serono SA
Route de Fenil / Zone industrielle B
1804 Corsier-sur-Vevey
Acces plan

Date & Schedule
Tuesday June, the 26th
17h30 Welcome
18h00 Introduction
18h10 First Conference

19h00 Q&A session
19h30 Networking cocktail
We encourage you to come with public transportation, as there is limited visitor parking on the site and nearby. Bus 212 from/to Vevey train station every 30 minutes.

Main partners
Event partners
Media partners

This event is free, but prior registration is mandatory. Don’t hesitate to forward this invitation. We are looking forward to seeing you on Tuesday June 26th at 18h00 @ Merck Serono, Corsier-sur-Vevey.

Best regards,
Rezonance - juin 2012


/rezo/classes/ft-first-tuesday/vaud/2012-06-26/one-community -- www.rezonance.ch --